FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134986656> ?p ?o ?g. }

• W3134986656 endingPage "175883592199343" @default.
• W3134986656 startingPage "175883592199343" @default.
• W3134986656 abstract "Tumor progression following endocrine therapy is considered to indicate resistance to endocrine drugs due to a variety of mechanisms. An insufficient dose of endocrine drugs is one of the causes for treatment failure in some patients with high hormone-receptor (HR)-expressing advanced breast cancer. This study aimed to explore the efficacy of high-dose tamoxifen (TAM) treatment in patients with advanced breast cancer with highly expressed HR.This was a single-arm, phase II pilot study that enrolled patients with advanced breast cancer with high HR expression (estrogen receptor ⩾60% and/or progesterone receptor ⩾60%) following routine endocrine therapy. All enrolled patients received a high-dose of TAM (100 mg/day) until disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate (ORR), clinical benefit rate (CBR), overall survival (OS), and safety. Exploratory endpoints included the predictive value of 16α-18F-17β-fluoroestradiol quantitative positron emission tomography/computed tomography (18F-FES PET/CT) for treatment efficacy.A total of 30 patients were enrolled between September 2017 and February 2019. The median PFS was 6 months [95% confidence interval (CI) 4.9-7.1] and the median OS was 15.6 months (95% CI 8.3-22.9). Five patients experienced a partial response (PR) and none experienced a complete response (CR), with an ORR of 16.7% and CBR of 33.3%. No severe adverse events were observed. Lesions with 18F-FES maximum standardized uptake value (SUVmax) ⩾4 had a significantly longer PFS [median 9.2 months, (95% CI 6.9-11.6)] compared with lesions with a 18F-FES SUVmax <4 [median 4.8 months, (95% CI 3.9-5.6); p = 0.022].A high-dose of TAM is effective and safe for patients with advanced breast cancer with high HR expression. 18F-FES SUVmax values may predict the local clinical benefits of high-dose TAM .[ClinicalTrials.gov identifier: NCT0304565]." @default.
• W3134986656 created "2021-03-15" @default.
• W3134986656 creator A5005765923 @default.
• W3134986656 creator A5007077962 @default.
• W3134986656 creator A5013871117 @default.
• W3134986656 creator A5014524491 @default.
• W3134986656 creator A5030507461 @default.
• W3134986656 creator A5043334299 @default.
• W3134986656 creator A5046774599 @default.
• W3134986656 creator A5049545916 @default.
• W3134986656 creator A5052517378 @default.
• W3134986656 creator A5056496295 @default.
• W3134986656 creator A5058283264 @default.
• W3134986656 creator A5077119545 @default.
• W3134986656 creator A5083140640 @default.
• W3134986656 creator A5089713962 @default.
• W3134986656 date "2021-01-01" @default.
• W3134986656 modified "2023-10-16" @default.
• W3134986656 title "High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study" @default.
• W3134986656 cites W119006202 @default.
• W3134986656 cites W1809083310 @default.
• W3134986656 cites W1988462970 @default.
• W3134986656 cites W2013373169 @default.
• W3134986656 cites W2026716154 @default.
• W3134986656 cites W2029475329 @default.
• W3134986656 cites W2037453576 @default.
• W3134986656 cites W2044190863 @default.
• W3134986656 cites W2087382494 @default.
• W3134986656 cites W2090954603 @default.
• W3134986656 cites W2095627442 @default.
• W3134986656 cites W2100506877 @default.
• W3134986656 cites W2113458582 @default.
• W3134986656 cites W2137478903 @default.
• W3134986656 cites W2144790402 @default.
• W3134986656 cites W2165946747 @default.
• W3134986656 cites W2168209981 @default.
• W3134986656 cites W2431602805 @default.
• W3134986656 cites W2460730117 @default.
• W3134986656 cites W250301019 @default.
• W3134986656 cites W2548000951 @default.
• W3134986656 cites W2752563952 @default.
• W3134986656 cites W2762481118 @default.
• W3134986656 cites W2969690362 @default.
• W3134986656 cites W4211032970 @default.
• W3134986656 doi "https://doi.org/10.1177/1758835921993436" @default.
• W3134986656 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7934038" @default.
• W3134986656 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33737962" @default.
• W3134986656 hasPublicationYear "2021" @default.
• W3134986656 type Work @default.
• W3134986656 sameAs 3134986656 @default.
• W3134986656 citedByCount "6" @default.
• W3134986656 countsByYear W31349866562021 @default.
• W3134986656 countsByYear W31349866562022 @default.
• W3134986656 countsByYear W31349866562023 @default.
• W3134986656 crossrefType "journal-article" @default.
• W3134986656 hasAuthorship W3134986656A5005765923 @default.
• W3134986656 hasAuthorship W3134986656A5007077962 @default.
• W3134986656 hasAuthorship W3134986656A5013871117 @default.
• W3134986656 hasAuthorship W3134986656A5014524491 @default.
• W3134986656 hasAuthorship W3134986656A5030507461 @default.
• W3134986656 hasAuthorship W3134986656A5043334299 @default.
• W3134986656 hasAuthorship W3134986656A5046774599 @default.
• W3134986656 hasAuthorship W3134986656A5049545916 @default.
• W3134986656 hasAuthorship W3134986656A5052517378 @default.
• W3134986656 hasAuthorship W3134986656A5056496295 @default.
• W3134986656 hasAuthorship W3134986656A5058283264 @default.
• W3134986656 hasAuthorship W3134986656A5077119545 @default.
• W3134986656 hasAuthorship W3134986656A5083140640 @default.
• W3134986656 hasAuthorship W3134986656A5089713962 @default.
• W3134986656 hasBestOaLocation W31349866561 @default.
• W3134986656 hasConcept C121608353 @default.
• W3134986656 hasConcept C126322002 @default.
• W3134986656 hasConcept C143998085 @default.
• W3134986656 hasConcept C197934379 @default.
• W3134986656 hasConcept C203092338 @default.
• W3134986656 hasConcept C2775930923 @default.
• W3134986656 hasConcept C2777176818 @default.
• W3134986656 hasConcept C2779984678 @default.
• W3134986656 hasConcept C31760486 @default.
• W3134986656 hasConcept C530470458 @default.
• W3134986656 hasConcept C535046627 @default.
• W3134986656 hasConcept C71924100 @default.
• W3134986656 hasConcept C84606932 @default.
• W3134986656 hasConceptScore W3134986656C121608353 @default.
• W3134986656 hasConceptScore W3134986656C126322002 @default.
• W3134986656 hasConceptScore W3134986656C143998085 @default.
• W3134986656 hasConceptScore W3134986656C197934379 @default.
• W3134986656 hasConceptScore W3134986656C203092338 @default.
• W3134986656 hasConceptScore W3134986656C2775930923 @default.
• W3134986656 hasConceptScore W3134986656C2777176818 @default.
• W3134986656 hasConceptScore W3134986656C2779984678 @default.
• W3134986656 hasConceptScore W3134986656C31760486 @default.
• W3134986656 hasConceptScore W3134986656C530470458 @default.
• W3134986656 hasConceptScore W3134986656C535046627 @default.
• W3134986656 hasConceptScore W3134986656C71924100 @default.
• W3134986656 hasConceptScore W3134986656C84606932 @default.
• W3134986656 hasLocation W31349866561 @default.
• W3134986656 hasLocation W31349866562 @default.

• next